Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Applicant’s election without traverse of a third ligand of claim 11 in the reply filed on October 1, 2025 is acknowledged.
CLAIM SECTION OBJECTION
Amendments to claims filed on June 8, 2025 list claims 64 and 65 present after claim 17 have been cancelled. Claim section further recites “wherein any substituent in the host --- and heteroaromatic analogs thereof.” before claim 18. Thus, such recitation is objected.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 19 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 19 recites “HOST Group defined herein.” without any listing of the HOST Group which is indefinite.
EXAMINER’S COMMENT REGARDING ALLOWABLE CLAIMS
The examiner was unable to find pertinent references regarding the elected third ligand of claim 11 and thus the third ligand of claim 11 would be allowable.
Thus, the examiner further searched and examined the recited generic Formula I of claim 1. Again, the examiner is unable to find pertinent references regarding the recited generic Formula I and species thereof.
Thus, claims 1-18 and 20 are allowed.
REASONS FOR ALLOWANCE
The following prior art is considered pertinent to applicant's disclosure.
WO 2005/123873 teaches ligands comprising a diazole or triazole group having a substituent at page 17-29, but failed to teach or suggest the instant five membered ring condensed with the diazole or triazole group.
WO 2007/004380 teaches ligands comprising a diazole group or an azole group comprising other hetero atom having a substituent at page 21-32, but failed to teach or suggest the instantt five membered ring condensed with the diazole or triazole group.
WO 2007/004380 teaches ligands comprising a triazole group condensed with a phenyl, but failed to teach or suggest the instant five membered ring condensed with the diazole or triazole group.
Alvarez et al. (Eur. J. Inorg. Chem. 2015, page 4921-4934) teach complexes with 3-(pyridin-2-yl)imidazo[1,5-a] comprising a diazole condensed with a six member ring in Schemes 1 and 2, but failed to teach or suggest the instant five membered ring condensed with the diazole group.
Takizawa et al. (Inorg. Chem. 2007, 46, pages 4308-4319) teach complexes with 3-(pyridin-2-yl)imidazo[1,5-a] comprising a diazole condensed with a six member ring in Schemes 1 and 2, but failed to teach or suggest the instant five membered ring condensed with the diazole group.
Huang et al. (Chem. Mater. 2004, 16, pages 2480-2488) teach Iridium complexes containing benzoimidazole-based ligands in Schemes 1 and 2, but failed to teach or suggest a five membered ring condensed with the diazole group. but failed to teach or suggest the instant five membered ring condensed with the diazole group.
US 7,393,599 and US 2002/0134984 A1 teach ligands comprising a diazole or triazole group having a substituent, but failed to teach or suggest the instant five membered ring condensed with the diazole or triazole group.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAE H YOON whose telephone number is (571)272-1128. The examiner can normally be reached Mon-Fri.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Jones can be reached at (571)270-7733. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TAE H YOON/Primary Examiner, Art Unit 1762